4.7 Article

Mast Cell Phenotype, Location, and Activation in Severe Asthma Data from the Severe Asthma Research Program

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1164/rccm.201002-0295OC

Keywords

prostaglandin D2; chymase; carboxypeptidase A

Funding

  1. National Institute of Health, Children's Healthcare of Atlanta Center for Developmental Lung Biology [HL69116, HL69130, HL69155, HL69167, HL69170, HL69174, HL69349, HL091762, KL2RR025009, M01 RR02635, M01 RR03186, M01 RR007122-14, 1 UL1RR024153, 1 UL1RR024989, 1 UL1RR024992, 1 UL1RR025008, 1 UL1RR025011]
  2. National Institutes of Health (NIH) [T32 F32]
  3. Asthmatx
  4. NIH-NHLBI
  5. Electrocore
  6. BMS
  7. GlaxoSmithKline
  8. Pharming
  9. Novartis
  10. PhadiaNCU in royalties
  11. NIH
  12. Philip Morris Research Foundations
  13. Amira
  14. AstraZeneca
  15. Boehringer-Ingelheim
  16. Centocor
  17. Genentech
  18. Merck/Schering Plough
  19. Pfizer
  20. Wyeth

Ask authors/readers for more resources

Rationale: Severe asthma (SA) remains poorly understood. Mast cells (MC) are implicated in asthma pathogenesis, but it remains unknown how their phenotype, location, and activation relate to asthma severity. Objectives: To compare MC-related markers measured in bronchoscopically obtained samples with clinically relevant parameters between normal subjects and subjects with asthma to clarify their pathobiologic importance. Methods: Endobronchial biopsies, epithelial brushings, and bronchoalveolar lavage were obtained from subjects with asthma and normal subjects from the Severe Asthma Research Program (N = 199). Tryptase, chymase, and carboxypeptidase A (CPA)3 were used to identify total MC (MCTot) and the MCTC subset (MCs positive for both tryptase and chymase) using immunostaining and quantitative real-time polymerase chain reaction. Lavage was analyzed for tryptase and prostaglandin D2 (PGD2) by ELISA. Measurements and Main Results: Submucosal MCTot (tryptase-positive by immunostaining) numbers were highest in mild asthma/no inhaled corticosteroid (ICS) therapy subjects and decreased with greater asthma severity (P = 0.002). In contrast, MCTC (chymase-positive by immunostaining) were the predominant (MCTC/MCTot > 50%) MC phenotype in SA (overall P = 0.005). Epithelial MC-rot were also highest in mild asthma/no ICS, but were not lower in SA. Instead, they persisted and were predominantly MCTC. Epithelial CPA3 and tryptase mRNA supported the immunostaining data (overall P = 0.008 and P = 0.02, respectively). Lavage PGD2 was higher in SA than in other steroid-treated groups (overall P = 0.02), whereas tryptase did not differentiate the groups. In statistical models, PGD2 and MCTC/MCTot predicted SA. Conclusions: Severe asthma is associated with a predominance of MCTC in the airway submucosa and epithelium. Activation of those MCTC may contribute to the increases in PGD2 levels. The data suggest an altered and active MC population contributes to SA pathology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available